Cystic Fibrosis:
Mucus Clearance & Regenerative Support

An integral, functional regenerative medicine approach

We utilize umbilical cord mesenchymal stem cells as the core therapeutic agent, integrated with physical therapy, nutritional medicine, and minimally invasive techniques. This protocol is designed as a supportive treatment alongside conventional CF care, aiming to slow degenerative progression, improve quality of life, and in select cases, contribute to disease stabilization. Our objective is verifiable functional support, to improve your quality of life.

— Dr. Quezada | Integral Regenerative Medicine | Verbatim Clinical Practice
Mucus Clearance Support Umbilical cord MSCs • Physical therapy • Nutritional medicine • Minimally invasive techniques

Eligibility & Best Candidates

This integral supportive therapy is clinically oriented toward individuals with a confirmed diagnosis of cystic fibrosis who present with impaired mucociliary clearance and progressive decline in pulmonary function despite optimized conventional treatment. Optimal candidates are those with stable extrapulmonary comorbidities, no active malignancy, and the capacity to participate in adjunctive physical therapy. Patients in advanced respiratory failure with invasive ventilatory support are generally not considered candidates. A comprehensive multidisciplinary evaluation determines appropriateness.

Best clinical results are observed in individuals with moderate disease severity (FEV₁ 40–70%) who demonstrate adherence to traditional pharmacologic and airway clearance techniques. Our approach is strictly adjunctive; we do not propose replacement of established CF care.

📅 Schedule a Free Virtual Consultation Contact us to arrange an initial conversation and consultation with a specialist. Meet Our Doctors →

Umbilical Cord Mesenchymal Stem Cells: Core Regenerative Support

At the foundation of this integral protocol are allogeneic umbilical cord mesenchymal stem cells (UC-MSCs), selected for their immunomodulatory and paracrine properties. Administered via minimally invasive techniques, these cells do not directly correct the CFTR defect; rather, they modulate the inflammatory microenvironment within the respiratory epithelium. Observed effects in clinical contexts include reduction in neutrophil-dominant inflammation, downregulation of pro-fibrotic cytokines, and improved mucociliary apparatus integrity. Physical therapy, including oscillatory positive expiratory pressure (OPEP) and autogenic drainage, is systematically integrated to potentiate airway clearance. Concomitant nutritional medicine addresses fat-soluble vitamin deficiencies and optimizes anabolic status. This multi-modal supportive strategy is intended to slow functional decline and, in some instances, has been associated with prolonged periods of disease non-progression. All claims are objective, verifiable, and do not imply curative outcome.

— The intervention is provided as an adjunct to conventional cystic fibrosis therapies; no replacement or curative intent is stated or implied.

UC-MSC immunomodulation Paracrine signaling • Minimally invasive delivery • Supportive microenvironment
Verifiable laboratory correlates
Learn More

Verbatim clinical practice statement: This therapeutic model integrates regenerative, physical, and nutritional modalities exclusively as complementary support. Umbilical cord mesenchymal stem cells are employed under institutional review board‑approved protocols. No claim of cure or replacement of standard cystic fibrosis care is made. Individual outcomes vary; disease progression may be modified in some cases. Objective functional metrics guide ongoing care.

Live Chat Free Consultation